In September 2023, Dana-Farber Cancer Institute, Beth Israel Deaconess Medical Center (BIDMC) and Harvard Medical Faculty Physicians at BIDMC (HMFP) announced a transformative clinical collaboration designed to reimagine cancer care in the Commonwealth. Together, we have a comprehensive plan to build the region's only dedicated, free-standing cancer hospital. We are devoted to providing the best care in the world and expanding access to highly specialized, expert cancer treatment.
We anticipated and welcomed the highly rigorous, thoughtful analysis by the Massachusetts Health Policy Commission (HPC). The final Cost and Market Impact Review (CMIR), approved today, marks the culmination of HPC's thorough review. We appreciate the Commission's vital role in helping ensure access to high-quality oncology services and containing healthcare costs. We thank the Health Policy Commission for their diligence.
"Dana-Farber Cancer Institute is a jewel in our state and our nation. Their dedicated staffs have cared for children, adults and their families during their most difficult moments. We are proud that Dana-Farber will be moving forward with Beth Israel Lahey Health system to build a new state-of-the-art facility-the future of cancer treatment and research-right here in Massachusetts. Massachusetts will continue to lead the world when it comes to finding lifesaving cures and innovative treatments because we know it is good for patients, families, and our economy," said Massachuetts Governor Maura Healey.
Known the world over for our compassionate, exceptional patient care, as well as our history of advancing revolutionary discoveries and groundbreaking innovations, our collaboration will invest in the people, infrastructure, resources, and technology with a single focus-- beating cancer and saving lives.
